Prostate specific antigen--a screening test for prostatic cancer?
- PMID: 2482112
- DOI: 10.1111/j.1464-410x.1989.tb05287.x
Prostate specific antigen--a screening test for prostatic cancer?
Abstract
A series of 287 patients referred by their family doctors with symptoms of bladder outflow obstruction were asked to attend the hospital for "pre-clinic" screening for carcinoma of prostate (CaP). Blood samples were collected from 211 patients and analysed for serum prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). Thirty-six patients had a serum PSA greater than 10 micrograms/l and 7 had PAP levels greater than 5 iu/l. In no instance was the PAP elevated without an associated increase in PSA concentration. Patients with raised markers underwent further investigations which included prostatic biopsy and/or resection; 17 patients were proved to have carcinoma of the prostate, 9 of whom had distant metastases. The specificity of PSA for detecting prostate cancer in this study was 90% with a sensitivity of 89.5%, in contrast to values for PAP of 100% and 36.8%. The routine use of PAP as a marker for prostatic cancer should be abandoned. The use of PSA as a screening test in a group of patients with prostatism appears justified, but with a positive predictive value of only 47%, its use in a mass unselected screening programme is not recommended.
Similar articles
-
A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.Clin Chim Acta. 1988 May 31;174(2):131-40. doi: 10.1016/0009-8981(88)90380-4. Clin Chim Acta. 1988. PMID: 2454767
-
Prostate-specific antigen (PSA) in the management of 500 prostatic patients.Am J Clin Oncol. 1988;11 Suppl 2:S61-2. doi: 10.1097/00000421-198801102-00013. Am J Clin Oncol. 1988. PMID: 2468274
-
Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.Scand J Urol Nephrol Suppl. 1991;138:97-103. Scand J Urol Nephrol Suppl. 1991. PMID: 1723815
-
Prostate-specific antigen in management of prostatic carcinoma.Urology. 1989 May;33(5 Suppl):11-6. doi: 10.1016/0090-4295(89)90100-3. Urology. 1989. PMID: 2469244 Review.
-
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.J Urol. 1991 May;145(5):907-23. doi: 10.1016/s0022-5347(17)38491-4. J Urol. 1991. PMID: 1707989 Review.
Cited by
-
Systematic review of clinical features of suspected prostate cancer in primary care.Can Fam Physician. 2015 Jan;61(1):e26-35. Can Fam Physician. 2015. PMID: 25756146 Free PMC article. Review.
-
Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers.Can Fam Physician. 2015 Jan;61(1):33-9. Can Fam Physician. 2015. PMID: 25756141 Free PMC article.
-
The effects of ejaculation on serum prostate-specific antigen (PSA).Int Urol Nephrol. 1998;30(1):53-8. doi: 10.1007/BF02550279. Int Urol Nephrol. 1998. PMID: 9569113 Clinical Trial.
-
Early detection of prostate cancer. Role of prostate-specific antigen.Can Fam Physician. 1996 Apr;42:709-12. Can Fam Physician. 1996. PMID: 8653039 Free PMC article. Review.
-
Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.CMAJ. 1991 Sep 1;145(5):413-28. CMAJ. 1991. PMID: 1878824 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous